Updates are available Correction dated 2021-01-29
Click to view Correction: https://0-doi-org.brum.beds.ac.uk/10.1186/s12885-021-07815-7
-
Authors
Yoneyama, Tohru
Hatakeyama, Shingo
Sutoh Yoneyama, Mihoko
Yoshiya, Taku
Uemura, Tsuyoshi
Ishizu, Takehiro
Suzuki, Minoru
Hachinohe, Shingo
Ishiyama, Shintaro
Nonaka, Motohiro
Fukuda, Michiko N.
Ohyama, Chikara
- License Information
-
More Information
Article History
Received: 10 November 2020
Accepted: 15 December 2020
First Online: 15 January 2021
Change Date: 29 January 2021
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via the original article.
Ethics approval and consent to participate
: All animal studies were carried out in accordance with recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All protocols were approved by the Hirosaki University Graduate School of Medicine Animal Care and Use Committee (permit numbers: M17022 and M19021), Kyoto University Animal Care and Use Committee (permit numbers: #34 and #36), and Aomori Prefecture Quantum Science Center Animal Care and Use Committee (permit numbers: DK001 and DK009).
: NA.
: Michiko N Fukuda is the founder of IF7CURE, INC., a company with development rights relevant to the peptide IF7C(RR)-SN38. The rest of authors declare that they have no competing interests.
